1Department of Radiation Oncology, Stanford University, Stanford, California. 2Stanford Cancer Institute, Stanford University, Stanford, California.

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

1Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain. 2Department of Basic Medical Sciences, Institute of Applied Molecular Medicine (IMMA), Facultad de Medicina, Universidad San Pablo ...

Publishing in July 2025 to coincide with the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning, the series will continue through December 2025! Technological ...

1Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois. *Corresponding Author: Hilary A. Kenny, Department of Obstetrics and Gynecology, ...

In a small investigator-initiated study, patients with early-stage mismatch repair–deficient solid cancers and minimal residual disease following surgery—determined by circulating tumor DNA—were found ...

The investigational HER2-selective tyrosine kinase inhibitor zongertinib appears remarkably effective in patients with HER2-mutant non–small cell lung cancer. Robust, durable responses were seen in ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.